[go: up one dir, main page]

AU2000264559A1 - Pharmaceutical compositions comprising a hmg coa reductase inhibitor - Google Patents

Pharmaceutical compositions comprising a hmg coa reductase inhibitor

Info

Publication number
AU2000264559A1
AU2000264559A1 AU2000264559A AU6455900A AU2000264559A1 AU 2000264559 A1 AU2000264559 A1 AU 2000264559A1 AU 2000264559 A AU2000264559 A AU 2000264559A AU 6455900 A AU6455900 A AU 6455900A AU 2000264559 A1 AU2000264559 A1 AU 2000264559A1
Authority
AU
Australia
Prior art keywords
pharmaceutical compositions
coa reductase
reductase inhibitor
hmg coa
hmg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2000264559A
Inventor
Norman Alfred Wiggins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2000264559(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2000264559A1 publication Critical patent/AU2000264559A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2000264559A 2000-01-26 2000-08-04 Pharmaceutical compositions comprising a hmg coa reductase inhibitor Abandoned AU2000264559A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0001621.2A GB0001621D0 (en) 2000-01-26 2000-01-26 Pharmaceutical compositions
GB0001621 2000-01-26
PCT/GB2000/003017 WO2001054669A1 (en) 2000-01-26 2000-08-04 Pharmaceutical compositions comprising a hmg coa reductase inhibitor

Publications (1)

Publication Number Publication Date
AU2000264559A1 true AU2000264559A1 (en) 2001-08-07

Family

ID=9884259

Family Applications (5)

Application Number Title Priority Date Filing Date
AU2000264559A Abandoned AU2000264559A1 (en) 2000-01-26 2000-08-04 Pharmaceutical compositions comprising a hmg coa reductase inhibitor
AU65800/00A Abandoned AU6580000A (en) 2000-01-26 2000-08-04 Pharmaceutical compositions comprising a hmg reductase inhibitor
AU51841/00A Expired AU738074B2 (en) 2000-01-26 2000-08-04 Pharmaceutical compositions
AU51842/00A Revoked AU781269C (en) 2000-01-26 2000-08-04 Pharmaceutical compositions
AU2005202392A Expired AU2005202392C1 (en) 2000-01-26 2005-06-02 Pharmaceutical compositions

Family Applications After (4)

Application Number Title Priority Date Filing Date
AU65800/00A Abandoned AU6580000A (en) 2000-01-26 2000-08-04 Pharmaceutical compositions comprising a hmg reductase inhibitor
AU51841/00A Expired AU738074B2 (en) 2000-01-26 2000-08-04 Pharmaceutical compositions
AU51842/00A Revoked AU781269C (en) 2000-01-26 2000-08-04 Pharmaceutical compositions
AU2005202392A Expired AU2005202392C1 (en) 2000-01-26 2005-06-02 Pharmaceutical compositions

Country Status (48)

Country Link
US (2) US6548513B1 (en)
EP (6) EP2266540A1 (en)
JP (3) JP4800467B2 (en)
KR (3) KR100388713B1 (en)
CN (3) CN100528161C (en)
AP (2) AP1879A (en)
AR (3) AR023624A1 (en)
AT (3) AT412062B (en)
AU (5) AU2000264559A1 (en)
BE (2) BE1013414A5 (en)
BG (4) BG65234B1 (en)
BR (2) BR0003364A (en)
CA (3) CA2315141C (en)
CH (2) CH691347A5 (en)
CL (1) CL2007001807A1 (en)
CR (3) CR6568A (en)
CZ (3) CZ290167B6 (en)
DE (3) DE10038110B4 (en)
DK (3) DK200001170A (en)
EE (3) EE04990B1 (en)
ES (2) ES2155043B1 (en)
FI (3) FI121365B (en)
FR (2) FR2795324B1 (en)
GB (3) GB0001621D0 (en)
HK (4) HK1047052A1 (en)
HR (3) HRP20020097B1 (en)
HU (2) HUP0003111A3 (en)
IL (4) IL150513A0 (en)
IS (3) IS1940B (en)
IT (2) ITTO20000780A1 (en)
ME (4) MEP33708A (en)
MY (2) MY123650A (en)
NL (2) NL1015859C2 (en)
NO (4) NO327675B1 (en)
NZ (2) NZ519774A (en)
PL (2) PL341855A1 (en)
PT (3) PT102503B (en)
RS (1) RS50201B (en)
RU (2) RU2264210C2 (en)
SE (2) SE523471C2 (en)
SI (1) SI1223918T1 (en)
SK (2) SK283872B6 (en)
TR (3) TR200701171T2 (en)
TW (2) TW553749B (en)
UA (2) UA51853C2 (en)
WO (2) WO2001054669A1 (en)
YU (1) YU52902A (en)
ZA (2) ZA200003998B (en)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
AU2001253287B2 (en) † 2000-04-10 2005-04-28 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
EP1911462A3 (en) * 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US7883721B2 (en) * 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
US20050175687A1 (en) * 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
US7842308B2 (en) * 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
KR20040026705A (en) * 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 Processes for preparing calcium salt forms of statins
US20060039967A1 (en) * 2002-08-12 2006-02-23 Motohiro Ohta Amino acid-containing chewable
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
SI21402A (en) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Lined particles and pharmaceutical forms
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
TW200526274A (en) * 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
EP1562912A2 (en) * 2003-08-28 2005-08-17 Teva Pharmaceutical Industries Limited Process for preparation of rosuvastatin calcium
UY28501A1 (en) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd CHEMICAL COMPOUNDS
US7829595B2 (en) * 2003-09-12 2010-11-09 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
TW200526596A (en) * 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
CA2546894C (en) * 2003-12-02 2009-09-08 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
AR048033A1 (en) * 2004-03-12 2006-03-22 Smithkline Beecham Plc PHARMACEUTICAL COMPOSITION TO MOLD COMPONENTS THAT INCLUDE COPOLIMERO OF POLY (MET) ACRYLATE, COVER, CONNECTOR OR SPACER OF CAPSULA MOLDED BY INJECTION THAT HAS THE PHARMACEUTICAL COMPOSITION AND FORM OF PHARMACEUTICAL MULTI-COMPONENT COMPONENTS
NZ550942A (en) * 2004-05-04 2011-02-25 Innophos Inc Directly compressible tricalcium phosphate
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
CN1323665C (en) * 2004-06-16 2007-07-04 鲁南制药集团股份有限公司 Composition for treating hyperlipemia
CA2573857A1 (en) * 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
KR20070052760A (en) * 2004-08-06 2007-05-22 트렌스폼 파마수티컬스 인코퍼레이티드 New fenofibrate formulations and related treatments
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
JP2008526781A (en) 2005-02-22 2008-07-24 テバ ファーマシューティカル インダストリーズ リミティド Manufacture of rosuvastatin
RU2303980C2 (en) * 2005-06-03 2007-08-10 ОАО "Щелковский витаминный завод" Medicinal formulation showing anti-aggregating effect and method for its preparing
JP2009515816A (en) * 2005-08-04 2009-04-16 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド Novel formulations comprising fenofibrate and statins and related methods of treatment
KR20070062996A (en) * 2005-08-16 2007-06-18 테바 파마슈티컬 인더스트리즈 리미티드 Crystalline Rosuvastatin Intermediate
PT1928409E (en) 2005-09-12 2012-11-27 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
WO2007052592A1 (en) * 2005-10-31 2007-05-10 Kowa Co., Ltd. Pharmaceutical preparation having excellent photostability
EP1968593B1 (en) * 2005-12-20 2017-08-23 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
WO2007125547A2 (en) * 2006-05-03 2007-11-08 Manne Satyanarayana Reddy Novel process for statins and its pharmaceutically acceptable salts thereof
HU227610B1 (en) * 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
SI2086945T1 (en) * 2006-10-09 2016-05-31 Msn Laboratories Private Limited Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
AU2008236616A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent
CN101336920B (en) * 2007-07-05 2013-06-05 江苏正大天晴药业股份有限公司 Stable medicine combination
EP2285353A1 (en) * 2008-01-30 2011-02-23 Lupin Limited Modified release formulations of hmg coa reductase inhibitors
WO2009112870A1 (en) * 2008-03-11 2009-09-17 Belupo-Lijekovi I Kozmetika D.D. Pharmaceutical composition comprising rosuvastatin calcium and magnesium carbonate hydroxide pentahydrate as a stabilizer
CA2725052C (en) 2008-05-27 2014-09-16 Changzhou Pharmaceutical Factory Co., Ltd. Preparation method of rosuvastatin calcium and its intermediates
EP2320876A2 (en) * 2008-06-13 2011-05-18 Pfizer Inc. Hydroxypropyl cellulose capsule shell
HRP20180077T1 (en) * 2008-06-27 2018-02-23 Krka, Tovarna Zdravil D.D., Novo Mesto PHARMACEUTICAL COMPOSITION CONTAINING STATIN
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
JP2011525901A (en) * 2008-06-27 2011-09-29 アブディ イブラヒム イラク サナイ ベ ティカレット アノニム シルケティ Rosuvastatin calcium-containing pharmaceutical composition
PL386051A1 (en) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stable, oral compound pharmaceutical containing pharmaceutically permissible content of [(E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3R,5S)-3,5-dihydroxy-hept-6-enoate acid salt
HU230877B1 (en) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stable combination medicine
MX344885B (en) * 2008-11-10 2017-01-10 Psicofarma S A De C V Process for obtaining a composition of rosuvastatin calcium and product obtained.
WO2010089770A2 (en) 2009-01-19 2010-08-12 Msn Laboratories Limited Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof
TR200902077A2 (en) 2009-03-17 2010-01-21 Sanovel İlaç San.Veti̇c.A.Ş. Stable rosuvastatin compositions
US8470805B2 (en) * 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
TR200904341A2 (en) 2009-06-03 2010-12-21 Bi̇lgi̇ç Mahmut Stable pharmaceutical compositions containing rosuvastatin calcium.
WO2011018185A2 (en) 2009-08-13 2011-02-17 Synthon B.V. Pharmaceutical tablet comprising rosuvastatin calcium
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
CN101766578B (en) * 2010-02-09 2011-06-08 鲁南贝特制药有限公司 Tablet containing Rosuvastatin calcium and preparation process thereof
TR201009397A2 (en) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Pharmaceutical compositions containing rosuvastatin.
EP2566465A2 (en) 2010-05-04 2013-03-13 Mahmut Bilgic Stable rosuvastatin formulations
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
TWI462739B (en) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Preparation and medical use of Sildenafil-homologous quaternary ammonium piperazine salt
EP2698159A4 (en) * 2011-04-12 2014-11-05 Sawai Seiyaku Kk Pitavastatin-containing preparation and method for producing same
EP2709592B1 (en) 2011-05-20 2017-08-16 AstraZeneca UK Limited Pharmaceutical composition of rosuvastatin calcium
RU2508109C2 (en) * 2011-05-27 2014-02-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Pharmaceutical composition for treating lipid storage disease
EP2851075B1 (en) * 2012-05-14 2021-12-01 Shionogi & Co., Ltd. Preparation containing 6,7-unsaturated-7-carbamoylmorphinan derivative
AR091706A1 (en) * 2012-07-11 2015-02-25 Teva Pharma LAQUINIMOD FORMULATIONS WITHOUT ALKALINIZING AGENTS
AU2014230304B2 (en) 2013-03-12 2018-07-05 Lg Chem, Ltd. Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
RO129060B1 (en) 2013-04-25 2014-11-28 Antibiotice S.A. Stable pharmaceutical composition with amorphous rosuvastatin calcium
RU2547574C2 (en) * 2013-07-09 2015-04-10 Общество с ограниченной ответственностью "Трейдсервис" Hypolipidemic dosage form and method for preparing it
KR101597004B1 (en) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 Pharmaceutical combination comprising sustained-release type metformin and immediate-release type HMG-CoA reductase inhibitor
EP3219318A4 (en) * 2014-11-11 2018-07-11 Shionogi & Co., Ltd. Multi-layered tablet containing drug unstable with respect to light
JP2016169198A (en) * 2015-03-13 2016-09-23 大原薬品工業株式会社 Tablets containing rosuvastatin calcium
JP6095176B2 (en) * 2015-04-24 2017-03-15 大原薬品工業株式会社 Film-coated tablets with improved photostability of rosuvastatin calcium
CN118975972A (en) 2015-10-23 2024-11-19 林德拉治疗公司 Gastric retention system for sustained release of therapeutic agents and method of use thereof
BR112018011636B1 (en) 2015-12-08 2024-03-12 Lyndra Therapeutics, Inc GASTRIC RESIDENCE SYSTEM FOR SUSTAINED RELEASE OF A THERAPEUTIC AGENT
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
CN119925721A (en) 2016-05-27 2025-05-06 林德拉治疗公司 Material Structure for Gastric Retention System
CN110022861B (en) 2016-09-30 2024-06-28 林德拉治疗公司 Gastric retention system for sustained release of adamantanes
CN107913257A (en) * 2016-10-10 2018-04-17 北京阜康仁生物制药科技有限公司 A kind of pharmaceutical composition comprising rosuvastain calcium and preparation method thereof
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
AU2018279853B2 (en) 2017-06-09 2024-07-04 Lyndra Therapeutics, Inc. Gastric residence systems with release rate-modulating films
JP2018027987A (en) * 2017-11-24 2018-02-22 共和薬品工業株式会社 Pharmaceutical composition
CN112274487A (en) * 2019-07-25 2021-01-29 北京福元医药股份有限公司 Rosuvastatin calcium pharmaceutical preparation
CN110638743B (en) * 2019-10-25 2023-03-28 乐普制药科技有限公司 Composition containing brivaracetam
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
GB2622822A (en) 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2262229A (en) * 1939-06-24 1941-11-11 Interchem Corp Pigment and method of preparation
GB653026A (en) 1947-07-02 1951-05-09 Merck & Co Inc Vitamin preparations
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4929620A (en) * 1987-12-10 1990-05-29 Warner-Lambert Company 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis
US4868185A (en) * 1987-12-10 1989-09-19 Warner-Lambert Company 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
NO890521L (en) 1988-02-25 1989-08-28 Bayer Ag SUBSTITUTED PYRIMIDINES.
US5030447A (en) 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
EP0367895A1 (en) * 1988-10-06 1990-05-16 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
US5004651A (en) 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
DK0475482T3 (en) 1990-09-13 1995-04-03 Akzo Nobel Nv Stabilized solid chemical agents
RU2086544C1 (en) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Benzenesulfonamide derivatives of pyrimidine or their salts, pharmaceutical composition for treatment of diseases associated with endothelin activity
JP2648897B2 (en) * 1991-07-01 1997-09-03 塩野義製薬株式会社 Pyrimidine derivatives
RU2098411C1 (en) * 1991-08-02 1997-12-10 Иституто Лусо Фармако д Италия С.п.А. Pyrimidine derivatives, method of their synthesis, pharmaceutical composition based on thereof
HU9203780D0 (en) 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5478832A (en) * 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
SG45369A1 (en) 1993-01-19 1998-10-16 Warner Lambert Co Stable oral ci-981 formulation and process of preparing same
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
CZ288545B6 (en) 1995-12-22 2001-07-11 Kowa Company, Ltd. Stabilized pharmaceutical composition based on (E)-3,5-dihydroxy-7-[4'-4"-fluorophenyl-2 -cyclopropylquinolin-3 -yl]-6-heptenoic acid
DE69713948D1 (en) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rapidly releasing pH-independent solid dosage forms containing cisapride
ES2242398T3 (en) 1998-06-05 2005-11-01 Warner-Lambert Company Llc STABILIZATION OF COMPOSITIONS CONTAINING INHIBITORS OF THE ANGIOTENSIN CONVERSION ENZYME USING MAGNESIUM OXIDE.
SI20109A (en) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stable pharmaceutical formulation
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
US6150410A (en) 1999-02-04 2000-11-21 Abbott Laboratories pH independent extended release pharmaceutical formulation
GB0000710D0 (en) 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
AR022462A1 (en) * 1999-02-06 2002-09-04 Astrazeneca Uk Ltd USE OF AN AGENT THAT DECREASES CHOLESTEROL
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
WO2001054688A1 (en) 2000-01-28 2001-08-02 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug

Also Published As

Publication number Publication date
GB0001621D0 (en) 2000-03-15
IS1940B (en) 2004-07-16
IS2805B (en) 2012-09-15
EP1223918A1 (en) 2002-07-24
HK1036934A1 (en) 2002-01-25
AR025055A1 (en) 2002-11-06
HRP20020632B1 (en) 2010-12-31
SE0002826D0 (en) 2000-08-04
PL341853A1 (en) 2001-01-29
AP2002002591A0 (en) 2002-09-30
GB0019029D0 (en) 2000-09-27
HUP0003110A3 (en) 2003-02-28
ES2171123A1 (en) 2002-08-16
FI111806B (en) 2003-09-30
HK1200368A1 (en) 2015-08-07
GB2358582A (en) 2001-08-01
ES2155043B1 (en) 2001-12-01
NZ531474A (en) 2007-04-27
KR20000072135A (en) 2000-12-05
HU0003111D0 (en) 2000-10-28
TR200200270T2 (en) 2002-06-21
AU2005202392B2 (en) 2008-11-20
JP2007182452A (en) 2007-07-19
CL2007001807A1 (en) 2008-01-18
GB2358582B (en) 2004-09-29
CR10114A (en) 2008-08-21
CZ20002883A3 (en) 2000-10-11
DE60001371T2 (en) 2004-01-22
AU2005202392C1 (en) 2016-06-02
EE05221B1 (en) 2009-10-15
NO2010005I1 (en) 2010-05-03
AR060248A2 (en) 2008-06-04
CA2313783A1 (en) 2000-10-16
HRP20020097B1 (en) 2010-12-31
HU0003110D0 (en) 2000-10-28
KR20010077840A (en) 2001-08-20
BG66159B1 (en) 2011-09-30
FI20001749A0 (en) 2000-08-04
ITTO20000779A1 (en) 2002-02-04
AU738074B2 (en) 2001-09-06
ZA200003997B (en) 2000-08-14
FR2804025A1 (en) 2001-07-27
NO20003967D0 (en) 2000-08-04
BG106926A (en) 2003-04-30
NO20003968D0 (en) 2000-08-04
BE1013413A3 (en) 2001-12-04
HUP0003111A3 (en) 2003-03-28
TR200701171T2 (en) 2007-04-24
IL187416A0 (en) 2008-02-09
EE05586B1 (en) 2012-10-15
JP2001206847A (en) 2001-07-31
RU2264210C2 (en) 2005-11-20
HK1047052A1 (en) 2003-02-07
CZ290167B6 (en) 2002-06-12
TR200201888T2 (en) 2002-11-21
IS6480A (en) 2002-07-23
DE60001371D1 (en) 2003-03-13
EP2018853A1 (en) 2009-01-28
IS8620A (en) 2007-03-07
TW553749B (en) 2003-09-21
AU781269B2 (en) 2005-05-12
NO20003968L (en) 2001-07-27
ITTO20000779A0 (en) 2000-08-04
AU2005202392A1 (en) 2005-06-30
ATA13612000A (en) 2004-02-15
CA2313783C (en) 2002-03-12
BR0003364A (en) 2001-09-18
CN100528161C (en) 2009-08-19
GB2358583B (en) 2002-02-06
FR2795324A1 (en) 2000-12-29
NL1015859A1 (en) 2001-07-27
HRP20020632A2 (en) 2004-12-31
CR6687A (en) 2005-07-18
CZ20002884A3 (en) 2001-09-12
IS6254A (en) 2002-01-29
FI20001749L (en) 2001-07-27
DK200001171A (en) 2001-07-27
CA2315141C (en) 2009-08-18
AP2002002409A0 (en) 2002-03-31
HRP20080525A2 (en) 2008-12-31
HK1040936B (en) 2010-06-11
PL196808B1 (en) 2008-02-29
AU5184200A (en) 2001-08-02
SE523471C2 (en) 2004-04-20
BG65234B1 (en) 2007-09-28
NO20003967L (en) 2001-07-27
CR6568A (en) 2004-03-05
NL1015859C2 (en) 2001-10-16
EE200200411A (en) 2003-12-15
UA77156C2 (en) 2006-11-15
NZ519774A (en) 2004-04-30
YU52902A (en) 2006-01-16
PT1223918E (en) 2003-06-30
ES2155043A1 (en) 2001-04-16
HRP20020097A2 (en) 2002-06-30
JP4800467B2 (en) 2011-10-26
CN101028268A (en) 2007-09-05
IL150513A (en) 2012-12-31
AT412063B (en) 2004-09-27
CZ298411B6 (en) 2007-09-26
CA2639407C (en) 2011-09-13
MY122707A (en) 2006-04-29
ME00202B (en) 2010-10-10
JP4800988B2 (en) 2011-10-26
JP3267960B2 (en) 2002-03-25
CH691347A5 (en) 2001-07-13
PT102504A (en) 2001-07-31
AT412062B (en) 2004-09-27
BR0003365A (en) 2001-09-18
DE10038110B4 (en) 2006-06-29
HK1040936A1 (en) 2002-06-28
EP2774609A1 (en) 2014-09-10
NO20071303L (en) 2001-07-27
AU6580000A (en) 2001-08-07
RS50201B (en) 2009-07-15
ITTO20000780A1 (en) 2000-11-04
CA2315141A1 (en) 2001-07-26
KR100698333B1 (en) 2007-03-23
AR023624A1 (en) 2002-09-04
NO327675B1 (en) 2009-09-07
PT102503B (en) 2004-02-27
FI121365B (en) 2010-10-29
TWI228050B (en) 2005-02-21
PL341855A1 (en) 2001-07-30
EP1251831A1 (en) 2002-10-30
EP1223918B1 (en) 2003-02-05
FI20105657L (en) 2010-06-10
BE1013414A5 (en) 2001-12-04
SE0002827D0 (en) 2000-08-04
DK178242B1 (en) 2015-09-28
AP1879A (en) 2008-08-14
HK1036935A1 (en) 2002-01-25
EE200200052A (en) 2003-04-15
EE200900047A (en) 2011-04-15
US6316460B1 (en) 2001-11-13
WO2001054668A1 (en) 2001-08-02
FR2804025B1 (en) 2002-08-23
SE523481C2 (en) 2004-04-20
MEP33808A (en) 2010-10-10
RU2206324C1 (en) 2003-06-20
IL147870A0 (en) 2002-08-14
MY123650A (en) 2006-05-31
CA2639407A1 (en) 2001-07-26
BG66168B1 (en) 2011-10-31
DK1223918T3 (en) 2003-04-28
SE0002827L (en) 2001-07-27
ZA200003998B (en) 2000-08-14
CN1149997C (en) 2004-05-19
DE10038108A1 (en) 2001-08-02
EP2266540A1 (en) 2010-12-29
EE04990B1 (en) 2008-04-15
IL147870A (en) 2003-10-31
ES2171123B1 (en) 2003-11-16
HUP0003110A2 (en) 2001-05-28
ATE232088T1 (en) 2003-02-15
UA51853C2 (en) 2002-12-16
US6548513B1 (en) 2003-04-15
IL150513A0 (en) 2003-02-12
SK283872B6 (en) 2004-03-02
PT102503A (en) 2000-12-29
SK11792000A3 (en) 2001-12-03
NO327554B1 (en) 2009-08-10
BG106393A (en) 2002-07-31
ME00191B (en) 2010-10-10
SI1223918T1 (en) 2003-06-30
HK1048950A1 (en) 2003-04-25
CZ299105B6 (en) 2008-04-23
HU222578B1 (en) 2003-08-28
SE0002826L (en) 2001-07-27
FR2795324B1 (en) 2002-05-17
AU5184100A (en) 2001-08-02
CN1319396A (en) 2001-10-31
CN1282581A (en) 2001-02-07
FI121589B (en) 2011-01-31
GB2358583A (en) 2001-08-01
NL1015858C2 (en) 2001-07-27
AU781269C (en) 2006-11-30
KR20030036492A (en) 2003-05-09
BG110353A (en) 2009-09-30
NO312434B1 (en) 2002-05-13
AP1449A (en) 2005-07-28
DK200001170A (en) 2001-01-27
MEP33708A (en) 2010-10-10
DE10038110A1 (en) 2001-08-23
HUP0003111A2 (en) 2002-02-28
FI20001750A0 (en) 2000-08-04
WO2001054669A1 (en) 2001-08-02
RU2002122752A (en) 2004-03-10
ATA13602000A (en) 2004-02-15
SK11782000A3 (en) 2001-12-03
FI20001750L (en) 2001-07-27
GB0019028D0 (en) 2000-09-27
JP2001206877A (en) 2001-07-31
CH700184B1 (en) 2010-07-15
EP2133070A1 (en) 2009-12-16
KR100388713B1 (en) 2003-06-25
YU5202A (en) 2004-12-31

Similar Documents

Publication Publication Date Title
AU2000264559A1 (en) Pharmaceutical compositions comprising a hmg coa reductase inhibitor
HUP0104258A3 (en) Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor
AU2001250420A1 (en) Pharmaceutical compositions
AU2001274307A1 (en) Pharmaceutical compositions
AU2002310798A1 (en) Pharmaceutical compositions comprising a hmg-coa reductase inhibitor
AU1530001A (en) Inhibitor compositions
AU2003250172A1 (en) Compositions comprising hmg-coa reductase inhibitor
AU2001273919A1 (en) Pharmaceutical compositions
PL369268A1 (en) A stable pharmaceutical composition of pravastatin
AU4085201A (en) Pharmaceutical composition
AU2002246659A1 (en) Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
AU3586401A (en) Pharmaceutical composition
AU2002246658A1 (en) Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
AU2001292578A1 (en) Pharmaceutical compounds
AUPQ906400A0 (en) Molluscicidal composition
AU2001278705A1 (en) Pharmaceutical composition
AU2002333193A1 (en) A pharmaceutical composition for dermal application
AU2003252358A1 (en) MEDICINAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR
AU2001228647A1 (en) Dihydrofolate reductase inhibitors
AU2002351722A1 (en) A pharmaceutical composition for dermal application
AU2001285737A1 (en) Pharmaceutical compositions
HK1061653A (en) A stable pharmaceutical composition of pravastatin
AUPQ875300A0 (en) A pharmaceutical composition
HK1053420A (en) Pharmaceutical compositions comprising fluvastatin
HK1036934B (en) Pharmaceutical compositions